A simple oral swab test before IVF likely to boost success rate
Swedish researchers have developed a simple oral swab test, which can help boost the success rate of the in vitro fertilization (IVF) procedure.
IVF treatment involves stimulating the woman's ovaries to mature many eggs, which are then retrieved and fertilised with sperm in the laboratory before being returned to the uterus.
There are two different types of hormone treatments to choose from for egg maturation: biological or synthetic. Besides the risk of serious side effects, the therapies sometimes require women to go into intensive care -- and many attempts at IVF fail. Selecting which therapy is best for the woman has become a major challenge.
While mapping genes is costly and takes time, the new simple oral swab test within an hour shows which hormone therapy is most suitable.
'Our hope is that this will reduce the risk of suffering for women, increase the number of successful treatments, and cut costs for taxpayers. Our goal is for the test to be available by the start of 2026,' said Yvonne Lundberg Giwercman, professor at Lund University.
A total of 1,466 women undergoing IVF treatment in Sweden were included in the study, and 475 were randomised to two different hormone treatments while the rest were controls.
Using gene sequencing, the team mapped the action of the gene follicle-stimulating hormone (FSH), which is known to play an important role in egg maturation.
The study identified that women with a particular variant of the FSH receptor (FSHR) gene that mediates the action of the hormone responded best to the biological hormone treatment, while others benefited from receiving the synthetic type of hormone.
To decode the genetic profile, the team turned to the oral swab test, which proved to be significantly efficient. Within an hour, it produced results that can be seen with the naked eye as a pink or yellow colour.
By knowing the woman's genetic profile in advance, we can increase the number of successful pregnancies, said Giwercman, in the study published in the journal Frontiers in Endocrinology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Neeri's giant leap with Global South Network for eco sustainability
Nagpur: The CSIR-National Environmental Engineering Research Institute (CSIR-NEERI) is set to establish a Global South Network to collaborate with institutes across Asia, Africa, Latin America, and Middle East on environmental sustainability. Tired of too many ads? go ad free now A key focus of this initiative is to address critical challenges affecting these regions. In an exclusive interview with TOI on Wednesday, CSIR-NEERI director Dr S Venkata Mohan, an Abdul Kalam Technology Innovation National Fellow, emphasized the network's goal of tackling region-specific environmental issues. "The Global South faces unique challenges, and this platform will amplify our voice to address them collaboratively," he said. The network aims to create a charter, facilitating annual engagements across member countries to develop tailored solutions. "India represents a significant population, and our contributions will carry substantial weight globally," Dr Venkata Mohan added. NEERI also hosts a regional centre for the Stockholm Convention on Persistent Organic Pollutants (POPs), in partnership with the ministry of environment, forest and climate change (MoEFCC). The Stockholm Convention targets chemicals that persist in the environment, spread globally, and accumulate in fatty tissues, posing risks to human health and ecosystems. "We are developing methods to monitor and phase out particulate organic carbon (POC) and other POPs," Dr Venkata Mohan said, highlighting NEERI's role as a recognized regional centre. The Global South Network, an independent initiative, will strengthen NEERI's leadership in environmental research, fostering sustainable development across member nations. Tired of too many ads? go ad free now Also, CSIR-NEERI is in discussion to establish a Centre of Excellence (CoE) in collaboration with IVL Swedish Environmental Research Institute to advance water and wastewater treatment and energy recovery technologies. "A recent Sweden delegation formalized to drive Indo-Swedish sustainability goals," he said. The CoE, to be established at NEERI's Nagpur campus, will serve as a hub for innovative water management solutions, aligning with global circular economy practices. Last year, the Swedish Innovation Agency Vinnova commissioned IVL Swedish Environmental Research Institute to conduct a pre-feasibility study for establishing a Sweden-India Centre of Excellence (CoE) for Sustainable Cities. The study was led by Rupali Deshmukh (Karangale), a native of Nagpur now based in Sweden, who serves as Country Manager for India and CEO of IVL India. IVL has now been tasked with hammering out a detailed feasibility study focusing on water, wastewater, sludge, and energy.
Time of India
2 days ago
- Time of India
Parkinson's disease four times more likely among people with autism, study suggests
New Delhi: People with autism could be four times more likely to develop Parkinson's disease later in life, according to a study among Swedish population. Autism is a neuro-developmental disorder affecting thought processes and social behaviour. It is diagnosed in early childhood, while Parkinson's disease is ageing-related neuro-degeneration, in which one experiences tremors in limbs and affected movement. "This indicates that there can be shared biological drivers behind ASD ( autism spectrum disorder ) and Parkinson's disease," first author Weiyao Yin, a researcher at the department of medical epidemiology and biostatistics, Karolinska Institutet, Sweden, said. The study, published in The Journal of the American Medical Association (JAMA) Neurology, analysed data from more than 22 lakh people born in the country between 1974 and 1999, who were followed from the age of 20 up to the end of 2022. Findings "suggest a potential shared etiology between neuro-developmental disorders and PD (Parkinson's disease), warranting increased awareness of long-term neurological conditions in individuals with ASD," the authors wrote. Yin said, "One hypothesis is that the brain's dopamine system is affected in both cases, since the neurotransmitter (brain chemical) dopamine plays an important part in social behaviour and motion control." While there is considerable evidence that dopamine production is affected in Parkinson's disease, the role of dopamine in autism is not yet clear, even though studies have shown that the brain chemical is involved, the researchers said. The researchers also took into account the fact that people diagnosed with autism are commonly prescribed anti-depressants and anti-psychotic drugs, which can cause Parkinson's-like symptoms. The link between autism and Parkinson's disease became less pronounced, "but the risk was still double", the researchers said. "The healthcare services need to keep people with ASD -- a vulnerable group with high co-morbidity and a high use of psychotropics -- under long-term observation," last author Sven Sandin, a statistician and epidemiologist at the department of medical epidemiology and biostatistics, Karolinska Institutet, said. "At the same time, it's important to remember that a Parkinson's diagnosis before the age of 50 is very rare, including for people with autism," Sandin said. The researchers pointed out that they only analysed early-onset Parkinson's disease before the age of 50 and that the average age of participants by the end of the study was 34. The incidence of Parkinson's disease was therefore very low -- 24 cases among 51,954 people with autism (0.05 per cent), and 438 among 22,26,611 people without autism (0.02 per cent). Future studies will need to examine if the elevated risk persists into older age, the team said. Global estimate of autism prevalence is one per cent, while in India, the estimate is 1.5 per cent, according to a 2023 study published in the Indian Journal of Pediatrics.
Hans India
6 days ago
- Hans India
Study shows impact of weight loss drugs on nerve cells in brain
New Delhi: Swedish researchers have tracked how nerve cells get activated by weight loss drugs such as semaglutide and how it affects the brain. Semaglutide belongs to a group of drugs called GLP-1R agonists and has been shown to effectively reduce food intake and body weight. The drug is already well established as part of the treatment for obesity and type 2 diabetes but can cause side effects such as nausea and muscle loss. In the study, researchers at the Sahlgrenska Academy at the University of Gothenburg showed that it is possible to distinguish the nerve cells in the brain that control the beneficial effects --such as reduced food intake and fat loss -- from those that contribute to side effects. To investigate how semaglutide affects the brain, the researchers worked with mice. They tracked which nerve cells were activated by the drug and were then able to stimulate these cells—without administering the drug itself. The results, published in the journal Cell Metabolism, revealed that the mice ate less and lost weight, just as they did when treated with semaglutide. When these nerve cells were killed, the drug's effect on appetite and fat loss instead decreased significantly. However, side effects such as nausea and muscle loss remained. "This suggests that these nerve cells control the beneficial effects of semaglutide. We have therefore identified a specific group of nerve cells that is necessary for the effects that semaglutide has on weight and appetite, but which does not appear to contribute to any significant extent to side effects such as nausea. "If we can target the treatment there, we may be able to maintain the positive effects while reducing side effects," says Júlia Teixidor-Deulofeu, first author of the study and Ph.D. student at Sahlgrenska Academy at the University of Gothenburg. The identified nerve cells are located in an area of the brain called the dorsal vagal complex. The team noted that the finding is not only an early step toward potentially improved treatment, but it also provides new knowledge about how semaglutide works in the brain. The study also provides deeper insight into how the brain stem regulates our energy balance.
